Patients suffering from acute gastroenteritis require appropriate intervention and treatment from physicians. Many gastrointestinal illnesses have similar or overlapping symptoms1, making it difficult to define a cause and adding complications to diagnosis.

For patients with Inflammatory Bowel Disease (IBD), the similar clinical presentations and laboratory findings in IBD relapse and enteric infections pose barrier to accurate diagnosis and treatment2. It is clinically imperative to differentiate an enteric infection from a flare-up to determine if the symptoms are from an infectious cause.

Traditional stool testing methods may involve several tests and have low sensitivity, prolonging time to accurate diagnosis3

Our Complete Solution

The BIOFIRE FILMARRAY Gastrointestinal (GI) Panel is a PCR-based qualitative multiplexed in vitro diagnostic test. Using the syndromic testing approach, the BIOFIRE GI Panel identifies simultaneously 22 gastrointestinal pathogens (bacteria, viruses, and parasites) in about 1 hour, from one patient stool sample. The BIOFIRE FILMARRAY GI Panel can be run directly on-site at your clinic, on the BIOFIRE FILMARRAY TORCH and 2.0 systems.

Compared to traditional stool testing, the BIOFIRE GI Panel :
Reduce time to result by 84%5


Increase diagnostic yield by more than 30%6 helping you to find the cause of GI illness more efficiently

Specifically, for IBD patients, during an exacerbation of symptoms, the BIOFIRE GI Panel has been shown to:
Have a higher rate of pathogen detection compared to traditional testing (26% vs 5%) in outpatients7
Detect enteric infection in 26.8% of tests, C. difficile being the most common infection2
Detect a non-C. difficile infection in 13,8% of tests2
Have a lower rate of IBS treatment modification compared to traditional testing (35% vs 64%)8

In addition, the BIOFIRE GI Panel is suggested to be used as a first diagnostic tool in patients suffering from IBD to target the subpopulations of patients needing diagnostic endoscopy9

With advanced molecular tests, physicians can better direct treatment strategies for IBD patients and more accurately pinpoint the cause of Gastrointestinal illness.

Learn more about our complete syndromic testing solutions or download the brochure below to view the economic advantages of the BIOFIRE FILMARRAY Gastrointestinal Panel.

DOWNLOAD THE BROCHURE

References:

  1. Riddle MS et al. Am J Gastroenterol. 2016; 111:602-622.
  2. Axelrad JE, et al. Inflamm Bowel Dis. 2017 Jun; 23(6):1034-1039.
  3. Shane AL et al. Clin Infect Dis. 2017;65(12): e45-e80.
  4. Overall performance based on prospective clinical study for the BioFire® FilmArray® Gastrointestinal Panel, data on file, BioFire Diagnostics.
  5. Beal S, et al. JCM. Jan 2018, 56 (1): JCM. 01457-17.
  6. Meyer j, et al. Scand J Gastroenterol. 2020; Dec;55(12):1405-1410.
  7. Hong S, et al. Inflamm Bowel Dis. 2021 Oct; 27(10):1634-1640.
  8. Ahmad W, et al. Dig Dis Sci. 2019 Feb; 64(2): 382–390.
  9. Meyer, J., J et al . Sci Rep 2022 12(1): 9730

Do you want to know about the gastro-intestinal flora?

Evidence of the role of microbiota has grown in recent years. Today, thanks to the highthroughput of Next Generation Sequencing1,2, you can study the dynamics of a patient’s microbiome and investigate its impact on patient health.

EPISEQ® 16S can accelerate the discovery of biomarkers with a very easy to use Software as a Service solution for data analysis with all statistical tool on board.

Contact us


By submitting this form, you agree to the processing of your personal data in accordance with our Privacy Statement.
LinkedIn Twitter Faceboook Instagram YouTube
BIOMÉRIEUX SA